FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody or its antigen-binding fragment capable of specifically binding to HBsAg, a method for production thereof, as well as to a pharmaceutical composition containing it. Also disclosed is an isolated nucleic acid molecule which codes said antibody or its antigen-binding fragment, as well as a vector and a host cell containing same.
EFFECT: invention is effective for treating or preventing HBV infection or a disease associated with HBV infection in a patient.
36 cl, 18 dwg, 7 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES FOR TREATMENT OF HEPATITIS B INFECTION AND RELATED DISEASES | 2018 |
|
RU2765878C2 |
ANTI-PRE-S1 HBV ANTIBODIES | 2016 |
|
RU2739955C2 |
C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
NOVEL ANTIBODIES TO BSSL | 2020 |
|
RU2826992C2 |
CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
ANTIBODIES TO S. AUREUS SURFACE DETERMINANTS | 2013 |
|
RU2698131C2 |
ANTIBODIES TO SURFACE DETERMINANTS OF S. AUREUS | 2013 |
|
RU2808018C2 |
ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
Authors
Dates
2024-02-29—Published
2020-05-22—Filed